DCM
REGN icon

Davis Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Davis Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.52K Hold
2
– – ﹤0.01% 441
2026
Q2 		$1.25K Buy
2
+1
+100% +$681 ﹤0.01% 455
2026
Q1 		$773 Hold
1
– – ﹤0.01% 362
2025
Q4 		$772 Hold
1
– – ﹤0.01% 354
2025
Q3 		$562 Buy
+1
New +$565 ﹤0.01% 392

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Davis Capital Management's REGN Position: Q3 2026 in Review

Davis Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 2 shares worth $1.52K. The position accounts for ﹤0.01% of the portfolio, ranked #441.

Davis Capital Management first reported a position in REGN in Q3 2025 and has held it in 5 quarters since. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Davis Capital Management held 2 shares of Regeneron Pharmaceuticals worth $1.52K as of Q3 2026.
  • Davis Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #441 holding.
  • Davis Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.